Charles River Laboratories International (NYSE:CRL) Share Price Crosses Above 200 Day Moving Average - Should You Sell?

Key Points

• CRL shares rose above their 200-day moving average, trading as high as $310.53 versus the $226.13 average, and last changed hands near $302.77.
• Analysts maintain a generally positive outlook, with a consensus rating of “Moderate Buy” and an average price target of $302.33, although targets range from $219 to $330.
• The company beat quarterly EPS and revenue expectations, but revenue declined 2.7% year over year and insiders sold 91,971 shares worth approximately $26 million over the past three months.

Charles River Laboratories International, Inc. (NYSE:CRL - Get Free Report)'s stock price crossed above its two hundred day moving average during trading on Wednesday. The stock has a two hundred day moving average of $226.13 and traded as high as $310.53. Charles River Laboratories International shares last traded at $302.7710, with a volume of 941,309 shares.

Analyst Ratings Changes

Several analysts have weighed in on CRL shares. Argus set a $330.00 price objective on shares of Charles River Laboratories International in a research note on Thursday, September 17th. Citigroup restated a "buy" rating on shares of Charles River Laboratories International in a research report on Wednesday, July 8th. Evercore set a $330.00 target price on shares of Charles River Laboratories International in a research report on Friday, September 25th. Royal Bank Of Canada raised their target price on shares of Charles River Laboratories International from $282.00 to $322.00 and gave the stock an "outperform" rating in a report on Friday, September 25th. Finally, CLSA downgraded shares of Charles River Laboratories International from an "outperform" rating to a "hold" rating and set a $219.00 price target for the company. in a research report on Monday, July 20th. Two research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Charles River Laboratories International has a consensus rating of "Moderate Buy" and an average price target of $302.33.

Charles River Laboratories International Trading Up 1.3%

The business has a 50-day moving average price of $288.02 and a two-hundred day moving average price of $226.13. The stock has a market capitalization of $14.45 billion, a P/E ratio of -62.43, a P/E/G ratio of 2.79 and a beta of 1.40. The company has a current ratio of 1.35, a quick ratio of 1.04 and a debt-to-equity ratio of 0.92.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its earnings results on Wednesday, August 5th. The medical research company reported $3.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.77 by $0.25. Charles River Laboratories International had a positive return on equity of 15.75% and a negative net margin of 5.96%. The company had revenue of $1 billion for the quarter, compared to analyst estimates of $980.53 million. During the same period in the prior year, the firm posted $3.12 EPS. Charles River Laboratories International's quarterly revenue was down 2.7% on a year-over-year basis. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. On average, analysts expect that Charles River Laboratories International, Inc. will post 11.38 EPS for the current fiscal year.

Insider Buying and Selling at Charles River Laboratories International

In other Charles River Laboratories International news, EVP Shannon Parisotto sold 981 shares of the stock in a transaction dated Monday, October 5th. The shares were sold at an average price of $308.44, for a total transaction of $302,579.64. Following the sale, the executive vice president directly owned 4,807 shares in the company, valued at $1,482,671.08. This represents a 16.95% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Nancy C. Andrews sold 573 shares of the stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $285.24, for a total transaction of $163,442.52. Following the sale, the director owned 1,438 shares in the company, valued at $410,175.12. The trade was a 28.49% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 91,971 shares of company stock valued at $26,033,968 over the last three months. 1.30% of the stock is owned by insiders.

Institutional Trading of Charles River Laboratories International

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Mather Group LLC. boosted its stake in Charles River Laboratories International by 657.7% in the third quarter. Mather Group LLC. now owns 591 shares of the medical research company's stock valued at $174,000 after buying an additional 513 shares in the last quarter. Triumph Capital Management grew its position in Charles River Laboratories International by 14,285.7% in the third quarter. Triumph Capital Management now owns 1,007 shares of the medical research company's stock valued at $297,000 after acquiring an additional 1,000 shares during the last quarter. Mitchell & Pahl Private Wealth LLC raised its stake in Charles River Laboratories International by 2.0% during the third quarter. Mitchell & Pahl Private Wealth LLC now owns 5,635 shares of the medical research company's stock worth $1,662,000 after acquiring an additional 112 shares in the last quarter. QRG Capital Management Inc. raised its stake in Charles River Laboratories International by 13.2% during the second quarter. QRG Capital Management Inc. now owns 2,183 shares of the medical research company's stock worth $495,000 after acquiring an additional 255 shares in the last quarter. Finally, Tidal Investments LLC raised its stake in Charles River Laboratories International by 26.5% during the second quarter. Tidal Investments LLC now owns 6,371 shares of the medical research company's stock worth $1,445,000 after acquiring an additional 1,334 shares in the last quarter. Institutional investors own 98.91% of the company's stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a contract research organization that provides products and services to support pharmaceutical, biotechnology and academic research. The company helps customers discover, develop and manufacture new medicines, vaccines and other healthcare products.

Its offerings include research models and related services, preclinical drug discovery, pharmacology, toxicology, bioanalysis and safety assessment. Charles River also provides laboratory and manufacturing solutions for biologics, cell and gene therapies, microbial testing and other specialized life sciences applications.

Founded in 1947, Charles River Laboratories serves customers worldwide through operations across North America, Europe and Asia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.